Atrial Fibrillation
Anthos Therapeutics Inc. is active in clinical research for atrial fibrillation, with studies centered on reducing the risk of ischemic stroke and systemic embolism in patients who are not suitable candidates for standard oral anticoagulation.
- Stroke prevention
- Systemic embolism
- Anticoagulation unsuitability
The sponsor’s interest in this area reflects a focus on thromboembolic risk management in patients with cardiac rhythm disorders.
Venous Thromboembolism
The company’s research portfolio includes venous thromboembolism treatment and recurrence prevention, with attention to patients following a recent VTE event and to outcomes related to bleeding risk during anticoagulant therapy.
- VTE recurrence prevention
- Bleeding risk
- Anticoagulant therapy
These studies place emphasis on balancing protection from clot recurrence with safety in long-term thrombotic disease management.
Cancer-Associated Thrombosis
Anthos Therapeutics also funds research in cancer-associated thrombosis, particularly venous thromboembolism in patients with gastrointestinal cancer and genitourinary cancer, where clot prevention and treatment remain clinically challenging.
- Gastrointestinal cancer
- Genitourinary cancer
- Oncology-related VTE
The sponsor’s activity in this domain is directed toward thrombotic complications arising in oncology populations.
Factor XIa Inhibition
The research program is built around abelacimab, a Factor XIa inhibitor studied across cardiovascular and thrombotic conditions, including atrial fibrillation and venous thromboembolism.
- Factor XIa
- Abelacimab
- Thrombosis prevention
This therapeutic focus connects anticoagulation research with efforts to address clot-related disease in both cardiac and cancer settings.
